Morse Asset Management Inc Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Morse Asset Management Inc boosted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3,144.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,300 shares of the biotechnology company’s stock after purchasing an additional 7,075 shares during the period. Morse Asset Management Inc’s holdings in ADMA Biologics were worth $125,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Perpetual Ltd bought a new stake in shares of ADMA Biologics in the fourth quarter valued at $62,300,000. Allspring Global Investments Holdings LLC raised its stake in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares during the period. B Group Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at $39,231,000. Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at $19,076,000. Finally, Principal Financial Group Inc. raised its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $19.88 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $8.75 and a 52-week high of $25.67. The firm has a market cap of $4.72 billion, a price-to-earnings ratio of 71.00 and a beta of 0.57. The business’s fifty day moving average is $20.28 and its 200 day moving average is $18.79.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics’s revenue was up 40.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share. Research analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ADMA shares. StockNews.com lowered ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Raymond James boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.